Samuel D. Waksal

Samuel D. Waksal
Born
Samuel David Waksal

(1947-09-08) September 8, 1947
Paris, France
CitizenshipUnited States
EducationPhD
Alma materOhio State University
OccupationsScientist, biotechnology executive, insider trader
Years active1979–present
Known forFounder of ImClone Systems and Kadmon Pharmaceuticals
Board member of
Cadus Corporation, Antigenics Inc., Test University, Rockefeller University
Criminal charges
fraud, conspiracy, perjury
Criminal penalty
87 months imprisonment
Criminal status
released
Preview warning: Page using Template:Infobox person with deprecated parameter alma_mater which should be merged with/replaced by education.
Preview warning: Using more than one of the following parameters in Template:Infobox person: alma_mater, education.

Samuel D. Waksal (born September 8, 1947) is the founder and former CEO of the biopharmaceutical company ImClone Systems. He is also the founder of Kadmon Pharmaceuticals, which was financed with private capital and commenced operations in New York City in 2010. At ImClone, Waksal led the company to develop the cancer drug Erbitux (cetuximab). During the course of its review process with the Food and Drug Administration (FDA) Waksal became involved in an insider trading scandal revolving around improper communications with personal friends and family members. He was convicted of several securities violations, served time in federal prison, and was released.